医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dai Nippon Printing and SCIVAX Enter into Capital and Operational Alliance in Foundry Business for Mass-production of Nanoimprinted Products

2023年04月03日 AM11:30
このエントリーをはてなブックマークに追加


 

TOKYO

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) and SCIVAX Co., Ltd. have entered into a capital and operational alliance regarding a foundry business designed to mass-produce nanoimprinted products. A production control joint venture, Nanoimprint Solutions Co., Ltd., (Nanosol) was established on April 3, 2023.

Our two companies will combine our strengths for the mass production of nanoimprinted products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005411/en/

Nanoimprint Solutions logo

Nanoimprint Solutions logo

[Background]

Nanoimprinting is expected to be used in a wide range of fields. These include 3D sensor devices, smart glasses, along with next-generation DNA sequencer bio-device elements.

In anticipation of future market expansion, we have entered into an operational alliance to ensure the stable supply of mass-produced nanoimprinted products.

[New Alliance]
We will combine DNP strengths in cutting-edge nanoimprint master mold manufacturing technology, mass production and quality control know-how, with SCIVAX strengths in mass-production manufacturing equipment capable of high-precision nanoimprinting, equipment design technology, and process know-how to further integrate the value chains of both of our companies.

As a result, we will develop a system in Japan that can rapidly respond to the mass production outsourcing needs, which will also lead to capabilities in responding to global supply chain risks.

We will choose to manufacture products at the best suited manufacturing plants of two companies, under production control conducted by Nanosol.

[New Company Summary]

Company name

Nanoimprint Solutions Co., Ltd.

Location

1-1-1 Ichigaya Kaga-cho, Shinjuku-ku, Tokyo

Capital

10 million yen

Business contents

Mass production management of nanoimprint contract business

Ownership stake

DNP 50%、SCIVAX 50%

[Future Prospects]
Through the newly established Nanosol, we will respond to the needs for mass production of nanoimprinted products for various applications. We aim for annual sales of approximately 10 billion yen by 2026.

More details

About DNP

DNP was established in 1876, and has become a leading global company that leverages print-based solutions to engineer fresh business opportunities while protecting the environment and creating a more vibrant world for all. We capitalize on core competencies in microfabrication and precision coating technology to provide products for the display, electronic device, and optical film markets. We have also developed new products, such as vapor chamber and reflect array that offer next-generation communication solutions for more people-friendly information society.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005411/en/

CONTACT

Media contact

DNP:

Yusuke Kitagawa, 81-3-6735-0101

kitagawa-y3@mail.dnp.co.jp

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続